ARRY-300
/ Novartis, Pfizer
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
January 18, 2014
MEK 1/2 inhibitors in the treatment of gynecologic malignancies
(Gynecol Oncol)
- “This paper reviews the translational evidence in favor of MEK inhibitors in cancer, their role in gynecologic malignancies, and details regarding the status of the fourteen MEK inhibitors currently being clinically tested: trametinib, selumetinib, pimasertib, refametinib, PD-0325901, MEK162, TAK733, RO5126766, WX-554, RO4987655, cobimetinib, AZD8330, MSC2015103B, and ARRY-300.”
Review • Oncology
1 to 1
Of
1
Go to page
1